Drug Interactions of Antidiabetics (Part 1) - PowerPoint PPT Presentation

About This Presentation
Title:

Drug Interactions of Antidiabetics (Part 1)

Description:

Diabetic patients take Insulin and/or other oral hypoglycemic and antihyperglycemic drugs to control their blood sugar levels. Along with antidiabetic medicines they may take drugs such as OTC medicines, prescription medicines, etc.to treat other illnesses which may interact with them. Drug interactions of Insulin with other drugs like Fluoroquinolones, Betablockers, Aspirin, Thiazolidinediones, Antipsychotics, Androgens, Antimalarials and Orlistat are dealt in this presentation. The interactions of Insulin with Complementary and alternative medicines (CAM) such as Bitter melon, Ginkgo, Ginseng, Gymnema, Licorice and Fenugreek with smoking and with alcohol are also dealt in this presentation. – PowerPoint PPT presentation

Number of Views:1938

less

Transcript and Presenter's Notes

Title: Drug Interactions of Antidiabetics (Part 1)


1
Drug Interactions of antidiabetics(part 1)
  • Dr.P.Naina Mohamed
  • Pharmacologist

2
Introduction
  • An adverse drug interaction is defined as an
    interaction between one or more coadministered
    medications which leads to alteration of the
    effectiveness or toxicity of any of the
    coadministered medications.
  • Drug interactions can be caused by prescription
    and over-the-counter (OTC) medications, herbal
    products or vitamins, foods, diseases, and
    genetics (family history).
  • It is estimated that people over 65 take an
    average of seven drugs at any one time to treat a
    variety of illnesses.
  • With this amount of medicine use, the probability
    that a person will take two prescribed drugs that
    may interact with one another is very high.

3
Antidiabetic Drugs
  • PARENTERAL ANTIDIABETIC DRUGS
  • Insulins
  • Rapid acting insulins
  • Regular insulin (Humulin R, Novolin R)
  • Insulin lispro (Humalog)
  • Insulin aspart (Novolog)
  • Insulin glulisine (Apidra)
  • Prompt insulin zinc (Semilente, Slightly slower
    acting)
  • Intermediate acting insulins include
  • Isophane insulin, neutral protamine Hagedorn
    (NPH) (Humulin N, Novolin N)
  • Insulin zinc (Lente)
  • Long acting insulins include
  • Extended insulin zinc insulin (Ultralente)
  • Insulin glargine (Lantus)
  • Insulin detemir (Levemir)
  • Incretin Mimetics (Glucagon-like peptide
    analogues)
  • Exenatide (Exendin-4, Byetta) - First GLP-1
    agonist.
  • Liraglutide (Victoza) - once-daily human
    analogue.
  • Taspoglutide - Presently in Phase III clinical
    trials.

4
Antidiabetic Drugs
  • ORAL ANTIDIABETIC DRUGS
  • Secretagogues
  • Sulfonylureas
  • First-generation agents
  • Tolbutamide (Orinase), Acetohexamide (Dymelor),
    Tolazamide (Tolinase), Chlorpropamide (Diabinese)
  • Second-generation agents
  • Glipizide (Glucotrol), Glyburide or Glibenclamide
    (Diabeta, Micronase, Glynase), Glimepiride
    (Amaryl), Gliclazide (Diamicron), Glycopyramide,
    Gliquidone.
  • Meglitinides
  • Repaglinide (Prandin)
  • Nateglinide (Starlix)
  • Insulin sensitizers
  • Biguanides
  • Metformin (Glucophage)
  • Thiazolidinediones (TZDs)
  • Rosiglitazone (Avandia)
  • Pioglitazone (Actos)

5
Antidiabetic Drugs
  • Alpha-glucosidase inhibitors
  • Acarbose (Precose/Glucobay)
  • Miglitol (Glyset)
  • Voglibose
  • Dipeptidylpeptidase-4 inhibitors
  • Sitagliptin (Januvia)
  • Vildagliptin (Galvus)
  • Saxagliptin (Onglyza)
  • Linagliptin (Tradjenta)
  • Aldose reductase inhibitors
  • Epalrestat
  • Sodium-glucose co-transporter 2 inhibitors
  • Dapagliflozin
  • Canagliflozin

6
Interactions of insulin
  • Insulin Drug Interactions
  • Insulin Fluoroquinolones Interaction
  • Insulin Beta blockers Interaction
  • Insulin Aspirin Interaction
  • Insulin Thiazolidinediones Interaction
  • Insulin Antipsychotics Interaction
  • Insulin Androgens Interaction
  • Insulin Antimalarials Interaction
  • Insulin Orlistat Interaction
  • Insulin CAM interactions
  • Insulin Bitter melon Interaction
  • Insulin Ginkgo Interaction
  • Insulin Ginseng Interaction
  • Insulin Gymnema Interaction
  • Insulin Fenugreek Interaction
  • Insulin Smoking interactions
  • Insulin Alcohol interactions

7
Insulin Fluoroquinolones
  • Insulin
  • Fluoroquinolones
  • Elevated risk of Hypoglycemia
  • Major and rapid interaction may occur between
    antidiabetics and FQs.
  • Closely monitor the blood glucose level and
    adjust the dose of the Insulin as indicated.
  • Dose adjustment may be required after
    discontinuation of a fluoroquinolone.
  • If a hypoglycemic reaction occurs, discontinue
    the fluoroquinolone, and contact a physician.

8
Insulin Beta blockers
  • Insulin
  • Beta blockers
  • Blockade of beta-2 receptors activity
  • Prevention of mobilisation of glucose from the
    liver
  • Recovery from hypoglycaemia is delayed
  • Rise in BP
  • Moderate and delayed interaction may occur
    between antidiabetics and Beta blockers.
  • Concurrent use can be uneventful but there are
    some risks.
  • The cardioselective beta blockers are probably
    safer than those that are non-selective.
  • The risk is greatest with propranolol

9
Insulin aspirin
  • Insulin
  • Aspirin
  • Additive blood glucose lowering effect
  • The interaction between the sulfonylureas or
    insulin and the salicylates is established but of
    limited importance.
  • Excessive and unwanted hypoglycaemia is very
    unlikely with small to moderate analgesic doses
    of salicylates. Some downward adjustment of the
    dose of the antidiabetic may be appropriate if
    large doses of salicylates are used.

10
Insulin thiazolidinediones
  • Insulin
  • Thiazolidinediones (Pioglitazone or
    rosiglitazone)
  • Thiazolidinediones may potentiate the renal
    effects of insulin on sodium and water retention
  • Increased incidence of exacerbation or
    precipitation of heart failure
  • As a result of a review, in October 2007 the
    European Medicines Agency concluded that the
    combination of rosiglitazone and insulin should
    only be used in exceptional cases and under close
    supervision, and this recommendation was not
    considered necessary for pioglitazone.
  • Similarly, in the US, pioglitazone is licensed
    for use with insulin, and the use of
    rosiglitazone with insulin is not recommended.
  • If oedema occurs in a patient taking a
    thiazolidinedione it has been recommended that
    the possible causes be assessed, and that if
    symptoms and signs suggest congestive heart
    failure, a dose change and temporary or permanent
    discontinuance of the thiazolidinedione should be
    considered.
  • Concurrent use of insulin and a thiazolidinedione
    also increases the incidence of hypoglycaemia. It
    has been noted that in patients receiving
    insulin, the insulin dose may need to be reduced
    by 10 to 25 if pioglitazone 15 or 30 mg daily
    is given.

11
Insulin Antipsychotics
  • Insulin
  • Chlorpromazine (Antipsychotics)
  • Inhibit the release of insulin induce
    adrenaline release from the adrenals
  • Rise in blood glucose levels
  • Other classical and atypical antipsychotics
    appear to act similarly.
  • Classical antipsychotics (haloperidol,
    pipamperone, levomepromazine, and zuclopenthixol)
    are associated with an increased risk of needing
    insulin.
  • Increased monitoring for glycaemic control,
    particularly when starting or stopping any
    classical or atypical antipsychotic in a patient
    with diabetes, is warranted.

12
Insulin anabolic steroids
  • Insulin
  • Androgens (nandrolone, methandienone,testosterone
    propionate or stanozolol)
  • Androgens improve insulin sensitivity
  • Enhanced reduction in blood glucose levels
  • A reduction in the dose requirements of insulin
    (of an average of one-third) may be expected in
    many patients with the steroids cited.

13
Insulin antimalarials
  • Insulin
  • Antimalarials (Hydroxychloroquine, chloroquine)
  • Inhibition of insulin degradation and induction
    of insulin secretion
  • Modest reduction in blood glucose
  • Hydroxychloroquine may reduce insulin
    requirements by about 25.
  • Similarly, hypoglycaemia has occurred in a
    patient taking chloroquine and insulin.

14
Insulin orlistat
  • Insulin
  • Orlistat
  • Orlistat helps to reduce weight
  • Improvement on glycaemic control
  • The benefits of orlistat on glycaemic control in
    overweight or obese patients with diabetes are
    established.
  • Antidiabetic treatment should be more closely
    monitored in patients taking orlistat, and the
    dose adjusted as necessary.

15
Insulin bitter melon
  • Insulin
  • Bitter melon
  • Bitter melon contains polypeptide P (vegetable
    insulin (v-insulin))
  • Insulin-like effects
  • Excacerbation of Hypoglycemia (manifested as
    blurred vision, tremor, intense hunger,
    generalized sweating, headache, palpitations,
    piloerection, lethargy, confusion, nervousness,
    and agitation)
  • Combination of Insulin and bitter melon may leads
    to rapid and moderately severe interaction.
  • Bitter melon is also known as bitter gourd,
    balsam pear, cundeamor and Karela.
  • Irregular consumption of Bitter melon as part of
    the diet could possibly contribute to unexplained
    fluctuations in diabetic control.

16
Insulin Ginkgo
  • Insulin
  • Ginkgo
  • May increase pancreatic beta-cell function
  • Further reductions of blood glucose
  • Combining Insulin with Ginkgo may produce delayed
    and moderately severe interaction.
  • Caution is advised if Ginkgo is taken with
    insulin.
  • Monitor blood glucose frequently, and monitor for
    signs and symptoms of hyperglycemia or
    hypoglycemia.

17
Insulin ginseng
  • Insulin
  • Ginseng
  • Additive hypoglycemic effect
  • Further reductions of Blood glucose
  • Combining insulin with ginseng may leads to
    delayed and moderately severe interaction.
  • Monitor blood glucose closely in patients taking
    ginseng with antidiabetic agents.
  • In patients having difficulty establishing blood
    glucose control, it is recommended to avoid
    concomitant use of ginseng and antidiabetic
    agents.

18
Insulin gymnema
  • Insulin
  • Gymnema extracts
  • Reduced blood glucose and glycosylated hemoglobin
  • Insulin moderately interacts with gymnema.
  • If patients choose to take gymnema with an
    antidiabetic agent, monitor blood glucose levels
    and signs and symptoms of hypoglycemia.

19
Insulin licorice
  • Insulin
  • Licorice
  • Synergistic effect
  • Hypokalemia and sodium retention
  • Moderate interaction is expected between insulin
    and licorice.
  • Caution is advised if licorice is used with
    insulin.
  • Advise patients that regular use of even moderate
    amounts of licorice can result in hypokalemia.

20
Insulin fenugreek
  • Insulin
  • Fenugreek
  • Improved peripheral glucose utilization,
  • Increased metabolic clearance rate of glucose
    delayed gastric emptying
  • Further reductions of blood glucose
  • Combining Insulin with fenugreek may cause rapid
    and moderately severe interaction.
  • Close monitoring of blood glucose is recommended
    for patients who choose to use fenugreek and
    antidiabetic agents concomitantly.

21
Insulin Smoking
  • Insulin
  • Smoking
  • Peripheral vasoconstriction
  • Decreased absorption of Insulin
  • Reduced therapeutic efficacy of Insulin

22
Insulin Smoking
  • Insulin
  • Smoking
  • Release of endogenous substances causing insulin
    resistance
  • Reduced therapeutic efficacy of Insulin
  • Smokers may require an increased insulin
    dosage.

23
Insulin Alcohol
  • Insulin
  • Alcohol
  • Inhibition of gluconeogenesis (formation of new
    glucose from amino acids)
  • Exacerbation of hypoglycaemia
  • Moderate and rapid interaction may occur between
    antidiabetics and alcohol.
  • Diabetes UK (formerly The British Diabetic
    Association) advises diabetics not to exceed 2
    drinks (for women) or 3 drinks (for men) daily.
  • Diabetics should not drink on empty stomach.
  • Diabetics with peripheral neuropathy should not
    have more than one drink daily.
  • Diabetic patients receiving insulin therapy
    should be advised to avoid excessive ethanol
    consumption.

24
Conclusion
  • The diabetics should consult their physician and
    pharmacist.
  • The diabetics should bring a list of all of the
    drugs they are taking (or simply bring the drugs
    themselves), including prescription drugs,
    over-the-counter drugs, and any supplements,
    herbal or otherwise, during their visit to the
    doctor or pharmacist.
  • They are encouraged to ask their doctor or
    pharmacist to look over their list for any
    potentially dangerous combinations.
  • It is recommended that people fill all their
    prescriptions at one pharmacy, if possible. In
    addition, they should maintain a list of all of
    their medicines and update it when one is added
    or removed.
  • They should review their list with their doctor
    or pharmacist regularly, particularly when they
    begin to take a new medicine.

25
References
  • Stockleys Drug Interactions, 9e
  • Karen Baxter
  • British National Formulary
  • June 2013
  • Basic Clinical Pharmacology, 12e Bertram
    G. Katzung, Susan B. Masters, Anthony J. Trevor
  • Goodman Gilman's The Pharmacological Basis of
    Therapeutics, 12e Laurence L. Brunton, Bruce
    A. Chabner, Björn C. Knollmann

26
References
  • http//www.ncbi.nlm.nih.gov/pmc/articles/PMC301938
    7/
  • http//spectrum.diabetesjournals.org/content/19/4/
    202.full.pdfhtml
  • http//www.fda.gov/cder/consumerinfo/druginteracti
    ons.htm
  • http//medicine.iupui.edu/clinpharm/ddis/
  • http//www.australianprescriber.com/magazine/24/4/
    83/5
  • www.micromedexsolutions.com
Write a Comment
User Comments (0)
About PowerShow.com